SCHEMBL23744767

SCHEMBL23744767

CNC(=O)c1cnc(N2C[C@@H](C)N[C@@H](C)C2)nc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.51
HDAC1 Q13547 14/20 0.46
HDAC6 Q9UBN7 14/20 0.43
HDAC3 O15379 13/20 0.43
HDAC4 P56524 13/20 0.43
HDAC7 Q8WUI4 13/20 0.43
HDAC2 Q92769 13/20 0.43
HDAC10 Q969S8 13/20 0.43
HDAC11 Q96DB2 13/20 0.43
HDAC8 Q9BY41 13/20 0.43
HDAC9 Q9UKV0 13/20 0.43
HDAC5 Q9UQL6 13/20 0.43
PARP1 P09874 1/20 0.41
BCL6 P41182 2/20 0.40
CHRM4 P08173 1/20 0.40
NCOR2 Q9Y618 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL25307507 0.83 HDAC6 (0.41) FGFR1HDAC1HDAC6HDAC3HDAC4
SCHEMBL64025 0.82 HDAC1 (0.43) FGFR1HDAC1HDAC6HDAC3HDAC4
SCHEMBL26089391 0.80 CHRM4 (0.45) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL23744330 0.79 DGAT2 (0.44) FGFR1HDAC1HDAC6HDAC3HDAC4
Hydrochloric Acid SCHEMBL23728063 0.78 DGAT2 (0.43) FGFR1HDAC1HDAC6HDAC3HDAC4
SCHEMBL24945764 0.76 PTPN11 (0.43) FGFR1HDAC1BCL6NCOR2
SCHEMBL23560975 0.76 HDAC6 (0.55) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL23744157 0.74 PTPN11 (0.44) FGFR1HDAC1BCL6NCOR2
SCHEMBL12525626 0.73 KDM1A (0.48) HDAC1HDAC6HDAC3HDAC4HDAC7
SCHEMBL12524713 0.73 PARP1 (0.46) HDAC1HDAC6HDAC3HDAC4HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4100410-B1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES INC (US) 2026-04-22 EP disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. 2023-04-27 US disclosed
WO-2021158698-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129359-A1 MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE CHRM4, CHRM2, CHRM5 FGFR1 1418/4885HDAC1 1545/4885HDAC6 1788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.